REGENXBIO Inc. (NASDAQ:RGNX) Director Argeris N. Karabelas Sells 10,000 Shares

REGENXBIO Inc. (NASDAQ:RGNX) Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the sale, the director now directly owns 11,286 shares of the company’s stock, valued at $114,101.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

REGENXBIO Price Performance

Shares of NASDAQ RGNX traded down $0.29 on Wednesday, hitting $9.92. The company’s stock had a trading volume of 749,278 shares, compared to its average volume of 608,384. The stock has a 50 day moving average of $12.20 and a 200-day moving average of $14.37. The company has a market capitalization of $490.25 million, a price-to-earnings ratio of -1.69 and a beta of 1.22. REGENXBIO Inc. has a 12-month low of $9.90 and a 12-month high of $28.80.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The company had revenue of $22.30 million during the quarter, compared to the consensus estimate of $22.97 million. During the same quarter in the previous year, the firm earned ($1.66) EPS. The company’s revenue was up 11.6% on a year-over-year basis. Sell-side analysts expect that REGENXBIO Inc. will post -4.66 EPS for the current fiscal year.

Institutional Trading of REGENXBIO

A number of institutional investors and hedge funds have recently modified their holdings of RGNX. Vanguard Group Inc. lifted its position in REGENXBIO by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock valued at $102,756,000 after purchasing an additional 436,043 shares during the period. Redmile Group LLC lifted its holdings in REGENXBIO by 21.0% during the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock worth $95,901,000 after purchasing an additional 790,866 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of REGENXBIO by 2.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,226,957 shares of the biotechnology company’s stock valued at $22,025,000 after buying an additional 34,385 shares during the period. Integral Health Asset Management LLC raised its position in REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after purchasing an additional 190,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in REGENXBIO by 258.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock worth $9,552,000 after purchasing an additional 588,773 shares in the last quarter. 88.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Barclays cut their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. HC Wainwright reiterated a “buy” rating and set a $39.00 price objective on shares of REGENXBIO in a research note on Wednesday, September 4th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Finally, The Goldman Sachs Group started coverage on shares of REGENXBIO in a report on Friday, June 7th. They set a “buy” rating and a $38.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.91.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.